BiopharmaVantage is pleased to announce that it has acted as advisor for a public traded investment company for its investment into next-generation transdermal drug delivery business. The UK based investee company is developing state-of-the art transdermal drug delivery patches for a variety of ailments using its innovative and proprietary platform.

BiopharmaVantage’s lead advisor, Dr Shreesh Saurya, managing the engagement commented: "Next generation transdermal drug delivery is an attractive are to be in. We have assessed the business leveraging our deep understanding of the sector, and believe that substantial value could be added using this platform both in the Rx and OTC settings. The investee company’s drug delivery platform is superior and would offer material competitive advantage. The investment will allow the investee company to progress the programs further, bring enhanced-value products to patients and create value for its all stakeholders.”

About BiopharmaVantage

BiopharmaVantage is a consulting firm that provides premium quality commercial due diligence services specifically for the healthcare sector. If you would like to discuss how we can assist you, then please contact us.

Contact:

Katherine Mae

Business Development Manager

BiopharmaVantage, Oxford, UK

Email: [email protected]

Strategy Solutions | Commercial Due Diligence | Competitive Intelligence | Valuation | Licensing & Partnering

Website: http://www.biopharmavantage.com